A 38-year-old woman presents with a painful vesicular rash in a dermatomal distribution on the left thorax. She reports severe burning pain and hyperesthesia. Regarding herpes zoster (shingles), all of the following are true EXCEPT:

Question

Accepted Answer

A. Varicella-zoster virus (VZV) reactivation is most commonly triggered by immunosuppression, advanced age, or malignancy, and zoster vaccine (Shingrix) is contraindicated in all immunocompromised patients. ## Analysis of Herpes Zoster Clinical Statements

### Correct Statements (Options 0, 1, 3)

**Option 0 — Dermatomal Distribution**
- Zoster rash is unilateral and respects the midline because it follows a single sensory dermatome
- Reactivation of latent VZV from a dorsal root ganglion → unilateral distribution
- Bilateral or midline-crossing rash suggests alternative diagnosis (e.g., disseminated VZV, HSV)

**Option 1 — Post-Herpetic Neuralgia (PHN)**
- PHN: pain persisting >30 days after rash onset
- Incidence and severity increase significantly with age (>50 years: 50% risk; >60 years: 75% risk)
- Can persist for months to years; severely impacts quality of life
- Risk factors: older age, severe acute pain, female sex, ophthalmic distribution

**Option 3 — Antiviral Therapy**
- Early initiation (within 72 hours of rash onset) is the standard of care
- Reduces acute pain duration and severity
- Decreases risk of PHN by ~50% when started early
- First-line agents: acyclovir, valacyclovir, famciclovir

### Incorrect Statement (Option 2) — **The Answer**

**Key Point:** Shingrix (recombinant zoster vaccine) is **NOT contraindicated in all immunocompromised patients** — the statement is too absolute and misleading.

| Vaccine Type | Immunocompetent | Immunocompromised | Notes |
|--------------|-----------------|-------------------|-------|
| **Shingrix (RZV)** | Recommended ≥50 years | **Recommended** in many groups | Inactivated vaccine; safe in HIV, transplant, on biologics |
| **Zostavax (ZVV)** | Older vaccine | **CONTRAINDICATED** | Live attenuated vaccine; risk of disseminated disease |

**Clinical Pearl:** Shingrix is an **inactivated recombinant vaccine** and is actually **recommended** in many immunocompromised populations (HIV with CD4 >200, solid organ transplant recipients, patients on TNF inhibitors). The older live-attenuated Zostavax is contraindicated in immunocompromised patients.

**Warning:** A common exam trap is confusing Shingrix (safe, inactivated) with Zostavax (contraindicated in immunocompromised). The statement's blanket contraindication is incorrect.

**High-Yield:** For NEET PG: Shingrix is safe and recommended in immunocompromised; Zostavax (live) is contraindicated.

Answer

B. The rash typically appears unilaterally and does not cross the midline because it follows the distribution of a single sensory nerve root

Answer

C. Post-herpetic neuralgia (PHN) is more common and severe in patients over 50 years of age and can persist for months to years after the rash resolves

Answer

D. Early antiviral therapy with acyclovir or valacyclovir initiated within 72 hours of rash onset reduces the duration and severity of acute pain and decreases the risk of PHN

A 38-year-old woman presents with a painful vesicular rash in a dermatomal distribution on the left thorax. She reports severe burning pain and hyperesthesia. Regarding herpes zoster (shingles), all of the following are true EXCEPT:

Explanation

Practice similar questions